← All Dr Reddys Laboratories LTD filings

Dr Reddys Laboratories LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NYSE
RDY
Dr Reddys Laboratories LTD
20-F: Dr. Reddy's Labs Reports Mixed Financial Results
Dr. Reddy's Laboratories Ltd. reported a 3% increase in overall revenues for the fiscal year ended March 31, 2026, driven by growth in Europe and India, but faced a 22% revenue decline in North America.
NYSE
RDY
Dr Reddys Laboratories LTD
20-F: Dr. Reddy's Reports Strong Revenue Growth Driven by Strategic Acquisitions and New Product Launches, Net Profit Growth Moderated by Higher Costs and Impairments
Dr. Reddy's Laboratories Limited announced a 17% increase in consolidated revenues for the fiscal year ended March 31, 2025, primarily fueled by strategic acquisitions and new product introductions, despite facing price erosion in key generic markets.
NYSE
RDY
Dr Reddys Laboratories LTD
20-F: Dr. Reddy's Laboratories 20-F Filing: Focus on Financial Reserves and Compliance
Dr. Reddy's Laboratories' 20-F filing highlights the company's financial reserves, derivative instruments, and compliance with various regulations.